Advertisement
Advertisement

ANAB

ANAB logo

AnaptysBio, Inc. Common Stock

47.38
USD
Sponsored
-0.47
-0.98%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

47.43

+0.05
+0.11%

ANAB Earnings Reports

Positive Surprise Ratio

ANAB beat 22 of 36 last estimates.

61%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$93.89M
/
$0.93
Implied change from Q3 25 (Revenue/ EPS)
+23.02%
/
+78.85%
Implied change from Q4 24 (Revenue/ EPS)
+117.78%
/
-229.17%

AnaptysBio, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, ANAB reported earnings of 0.52 USD per share (EPS) for Q3 25, beating the estimate of -1.46 USD, resulting in a 135.42% surprise. Revenue reached 76.32 million, compared to an expected 16.13 million, with a 373.23% difference. The market reacted with a +3.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of 0.93 USD, with revenue projected to reach 93.89 million USD, implying an increase of 78.85% EPS, and increase of 23.02% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, AnaptysBio, Inc. Common Stock reported EPS of $0.52, beating estimates by 135.42%, and revenue of $76.32M, 373.23% above expectations.
The stock price moved up 3.63%, changed from $34.74 before the earnings release to $36.00 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 13 analysts, AnaptysBio, Inc. Common Stock is expected to report EPS of $0.93 and revenue of $93.89M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement